{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:43:05Z","timestamp":1791654185275,"version":"4.3.4"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,5,4]],"date-time":"2010-05-04T00:00:00Z","timestamp":1272931200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1038\/nrneph.2010.58","type":"journal-article","created":{"date-parts":[[2010,5,4]],"date-time":"2010-05-04T04:41:20Z","timestamp":1272948080000},"page":"319-330","source":"Crossref","is-referenced-by-count":271,"title":["The RAAS in the pathogenesis and treatment of diabetic nephropathy"],"prefix":"10.1038","volume":"6","author":[{"given":"Piero","family":"Ruggenenti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cravedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,5,4]]},"reference":[{"key":"BFnrneph201058_CR1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/08037050310001057","volume":"12","author":"E Kaschina","year":"2003","unstructured":"Kaschina, E. & Unger, T. Angiotensin AT1\/AT2 receptors: regulation, signalling and function. Blood Press. 12, 70\u201388 (2003).","journal-title":"Blood Press."},{"key":"BFnrneph201058_CR2","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1291\/hypres.26.349","volume":"26","author":"T Morgan","year":"2003","unstructured":"Morgan, T. Renin, angiotensin, sodium and organ damage. Hypertens. Res. 26, 349\u2013354 (2003).","journal-title":"Hypertens. Res."},{"key":"BFnrneph201058_CR3","first-page":"328","volume":"21","author":"RC Harris","year":"1995","unstructured":"Harris, R. C. & Martinez-Maldonado, M. Angiotensin II-mediated renal injury. Miner. Electrolyte Metab. 21, 328\u2013335 (1995).","journal-title":"Miner. Electrolyte Metab."},{"key":"BFnrneph201058_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.semnephrol.2003.11.010","volume":"24","author":"PRG Ruggenenti","year":"2004","unstructured":"Ruggenenti, P. R. G. Introduction. Semin. Nephrol. 24, 91\u201392 (2004).","journal-title":"Semin. Nephrol."},{"key":"BFnrneph201058_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3317\/jraas.2006.003","volume":"7","author":"CM Ferrario","year":"2006","unstructured":"Ferrario, C. M. Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J. Renin Angiotensin Aldosterone Syst. 7, 3\u201314 (2006).","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"BFnrneph201058_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.amjmed.2003.09.034","volume":"116","author":"UC Brewster","year":"2004","unstructured":"Brewster, U. C. & Perazella, M. A. The renin\u2013angiotensin\u2013aldosterone system and the kidney: effects on kidney disease. Am. J. Med. 116, 263\u2013272 (2004).","journal-title":"Am. J. Med."},{"key":"BFnrneph201058_CR7","doi-asserted-by":"publisher","first-page":"16S","DOI":"10.1016\/j.amjhyper.2004.08.004","volume":"17","author":"ME Cooper","year":"2004","unstructured":"Cooper, M. E. The role of the renin\u2013angiotensin\u2013aldosterone system in diabetes and its vascular complications. Am. J. Hypertens. 17, 16S\u201320S (2004).","journal-title":"Am. J. Hypertens."},{"key":"BFnrneph201058_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1210\/er.2003-0001","volume":"24","author":"RM Carey","year":"2003","unstructured":"Carey, R. M. & Siragy, H. M. Newly recognized components of the renin\u2013angiotensin system: potential roles in cardiovascular and renal regulation. Endocr. Rev. 24, 261\u2013271 (2003).","journal-title":"Endocr. Rev."},{"key":"BFnrneph201058_CR9","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1681\/ASN.V1341100","volume":"13","author":"KF Hilgers","year":"2002","unstructured":"Hilgers, K. F. & Mann, J. F. ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. J. Am. Soc. Nephrol. 13, 1100\u20131108 (2002).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201058_CR10","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1161\/01.HYP.33.5.1237","volume":"33","author":"HM Siragy","year":"1999","unstructured":"Siragy, H. M. & Carey, R. M. Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension 33, 1237\u20131242 (1999).","journal-title":"Hypertension"},{"key":"BFnrneph201058_CR11","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1161\/01.HYP.0000193498.07087.83","volume":"46","author":"TL Reudelhuber","year":"2005","unstructured":"Reudelhuber, T. L. The continuing saga of the AT2 receptor: a case of the good, the bad, and the innocuous. Hypertension 46, 1261\u20131262 (2005).","journal-title":"Hypertension"},{"key":"BFnrneph201058_CR12","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1161\/01.RES.0000019892.41157.24","volume":"90","author":"JS Silvestre","year":"2002","unstructured":"Silvestre, J. S. et al. Antiangiogenic effect of angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb. Circ. Res. 90, 1072\u20131079 (2002).","journal-title":"Circ. Res."},{"key":"BFnrneph201058_CR13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1126\/science.191908","volume":"196","author":"MA Ondetti","year":"1977","unstructured":"Ondetti, M. A., Rubin, B. & Cushman, D. W. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 196, 441\u2013444 (1977).","journal-title":"Science"},{"key":"BFnrneph201058_CR14","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1172\/JCI112521","volume":"77","author":"R Zatz","year":"1986","unstructured":"Zatz, R. et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J. Clin. Invest. 77, 1925\u20131930 (1986).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph201058_CR15","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/nrd2685","volume":"7","author":"N Perico","year":"2008","unstructured":"Perico, N., Benigni, A. & Remuzzi, G. Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection. Nat. Rev. Drug Discov. 7, 936\u2013953 (2008).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnrneph201058_CR16","doi-asserted-by":"crossref","unstructured":"[No authors listed] Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN group. Lancet 349, 1857\u20131863 (1997).","DOI":"10.1016\/S0140-6736(96)11445-8"},{"key":"BFnrneph201058_CR17","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis, E. J., Hunsicker, L. G., Bain, R. P. & Rohde, R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329, 1456\u20131462 (1993).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201058_CR18","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1056\/NEJM198512263132601","volume":"313","author":"Y Taguma","year":"1985","unstructured":"Taguma, Y. et al. Effect of captopril on heavy proteinuria in azotemic diabetics. N. Engl. J. Med. 313, 1617\u20131620 (1985).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201058_CR19","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/bmj.304.6823.339","volume":"304","author":"S Bjorck","year":"1992","unstructured":"Bjorck, S., Mulec, H., Johnsen, S. A., Nord\u00e9n, G. & Aurell, M. Renal protective effect of enalapril in diabetic nephropathy. BMJ 304, 339\u2013343 (1992).","journal-title":"BMJ"},{"key":"BFnrneph201058_CR20","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1136\/bmj.297.6656.1086","volume":"297","author":"HH Parving","year":"1988","unstructured":"Parving, H. H., Hommel, E. & Smidt, U. M. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. BMJ 297, 1086\u20131091 (1988).","journal-title":"BMJ"},{"key":"BFnrneph201058_CR21","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861\u2013869 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201058_CR22","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851\u2013860 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201058_CR23","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","volume":"110","author":"D de Zeeuw","year":"2004","unstructured":"de Zeeuw, D. et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110, 921\u2013927 (2004).","journal-title":"Circulation"},{"key":"BFnrneph201058_CR24","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/S0140-6736(05)67814-2","volume":"366","author":"JP Casas","year":"2005","unstructured":"Casas, J. P. et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366, 2026\u20132033 (2005).","journal-title":"Lancet"},{"key":"BFnrneph201058_CR25","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(06)69172-1","volume":"368","author":"G Remuzzi","year":"2006","unstructured":"Remuzzi, G. & Ruggenenti, P. Overview of randomised trials of ACE inhibitors. Lancet 368, 555\u2013556 (2006).","journal-title":"Lancet"},{"key":"BFnrneph201058_CR26","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1172\/JCI112521","volume":"77","author":"R Zatz","year":"1986","unstructured":"Zatz, R. et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J. Clin. Invest. 77, 1925 (1986).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph201058_CR27","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1681\/ASN.V541139","volume":"5","author":"N Perico","year":"1994","unstructured":"Perico, N. et al. Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started. J. Am. Soc. Nephrol. 5, 1139\u20131146 (1994).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201058_CR28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.1994.03510280037029","volume":"271","author":"G Viberti","year":"1994","unstructured":"Viberti, G., Mogensen, C. E., Groop, L. C. & Pauls, J. F. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 271, 275\u2013279 (1994).","journal-title":"JAMA"},{"key":"BFnrneph201058_CR29","doi-asserted-by":"crossref","unstructured":"ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann. Intern. Med. 134, 370\u2013379 (2001).","DOI":"10.7326\/0003-4819-134-5-200103060-00009"},{"key":"BFnrneph201058_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s11906-002-0069-3","volume":"4","author":"HH Parving","year":"2002","unstructured":"Parving, H. H. & Hovind, P. Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy. Curr. Hypertens. Rep. 4, 387\u2013393 (2002).","journal-title":"Curr. Hypertens. Rep."},{"key":"BFnrneph201058_CR31","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Yusuf, S. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342, 145\u2013153 (2000).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201058_CR32","doi-asserted-by":"crossref","unstructured":"[No authors listed] Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 355, 253\u2013259 (2000).","DOI":"10.1016\/S0140-6736(99)12323-7"},{"key":"BFnrneph201058_CR33","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1056\/NEJMoa011489","volume":"345","author":"HH Parving","year":"2001","unstructured":"Parving, H. H. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 345, 870\u2013878 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201058_CR34","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1136\/bmj.314.7083.783","volume":"314","author":"M-A Gall","year":"1997","unstructured":"Gall, M.-A., Hougaard, P., Borch-Johnsen, K. & Parving, H.-H. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 314, 783\u2013788 (1997).","journal-title":"BMJ"},{"key":"BFnrneph201058_CR35","volume-title":"Brenner & Rector's The Kidney","author":"BM Brenner","year":"2008","unstructured":"Brenner, B. M. (Ed.) Brenner & Rector's The Kidney (W. B. Saunders, Philadelphia, 2008)."},{"key":"BFnrneph201058_CR36","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.2337\/diacare.27.6.1330","volume":"27","author":"DT Eurich","year":"2004","unstructured":"Eurich, D. T., Majumdar, S. R., Tsuyuki, R. T. & Johnson, J. A. Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes. Diabetes Care 27, 1330\u20131334 (2004).","journal-title":"Diabetes Care"},{"key":"BFnrneph201058_CR37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","volume":"63","author":"AI Adler","year":"2003","unstructured":"Adler, A. I. et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 63, 225\u2013232 (2003).","journal-title":"Kidney Int."},{"key":"BFnrneph201058_CR38","doi-asserted-by":"crossref","unstructured":"[No authors listed] Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 349, 1787\u20131792 (1997).","DOI":"10.1016\/S0140-6736(96)10244-0"},{"key":"BFnrneph201058_CR39","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/S0140-6736(08)61412-9","volume":"372","author":"N Chaturvedi","year":"2008","unstructured":"Chaturvedi, N. et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 372, 1394\u20131402 (2008).","journal-title":"Lancet"},{"key":"BFnrneph201058_CR40","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1056\/NEJMoa0808400","volume":"361","author":"M Mauer","year":"2009","unstructured":"Mauer, M. et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N. Engl. J. Med. 361, 40\u201351 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201058_CR41","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0168-8227(01)00288-1","volume":"54","author":"S Baba","year":"2001","unstructured":"Baba, S. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res. Clin. Pract. 54, 191\u2013201 (2001).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"BFnrneph201058_CR42","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa042167","volume":"351","author":"P Ruggenenti","year":"2004","unstructured":"Ruggenenti, P. et al. Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med. 351, 1941\u20131951 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201058_CR43","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1681\/ASN.2006060560","volume":"17","author":"P Ruggenenti","year":"2006","unstructured":"Ruggenenti, P., Perna, A., Ganeva, M., Ene-Iordache, B. & Remuzzi, G. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J. Am. Soc. Nephrol. 17, 3472\u20133481 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201058_CR44","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/01.hjh.0000202820.56201.e6","volume":"24","author":"H Haller","year":"2006","unstructured":"Haller, H. et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J. Hypertens. 24, 403\u2013408 (2006).","journal-title":"J. Hypertens."},{"key":"BFnrneph201058_CR45","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMicm066227","volume":"358","author":"A Patel","year":"2008","unstructured":"Patel, A. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560\u20132572 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201058_CR46","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJM199803053381003","volume":"338","author":"RO Estacio","year":"1998","unstructured":"Estacio, R. O. et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N. Engl. J. Med. 338, 645\u2013652 (1998).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201058_CR47","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","volume":"359","author":"LH Lindholm","year":"2002","unstructured":"Lindholm, L. H. et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359, 1004\u20131010 (2002).","journal-title":"Lancet"},{"key":"BFnrneph201058_CR48","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/S0140-6736(02)09072-4","volume":"359","author":"JM Bloom","year":"2002","unstructured":"Bloom, J. M. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study. Lancet 359, 2201 (2002).","journal-title":"Lancet"},{"key":"BFnrneph201058_CR49","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1161\/CIRCULATIONAHA.105.606962","volume":"113","author":"B Williams","year":"2006","unstructured":"Williams, B. et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113, 1213\u20131225 (2006).","journal-title":"Circulation"},{"key":"BFnrneph201058_CR50","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1056\/NEJMoa042274","volume":"351","author":"AH Barnett","year":"2004","unstructured":"Barnett, A. H. et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N. Engl. J. Med. 351, 1952\u20131961 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201058_CR51","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jacc.2005.05.051","volume":"46","author":"H Abuissa","year":"2005","unstructured":"Abuissa, H., Jones, P. G., Marso, S. P. & O'Keefe, J. H. Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J. Am. Coll. Cardiol. 46, 821\u2013826 (2005).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrneph201058_CR52","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1056\/NEJMoa065061","volume":"355","author":"TDT Investigators","year":"2006","unstructured":"Investigators, T. D. T. Effect of ramipril on the incidence of diabetes. N. Engl. J. Med. 355, 1551\u20131562 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201058_CR53","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.2215\/CJN.04140907","volume":"3","author":"P Ruggenenti","year":"2008","unstructured":"Ruggenenti, P., Bettinaglio, P., Pinares, F. & Remuzzi, G. Angiotensin converting enzyme insertion\/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. Clin. J. Am. Soc. Nephrol. 3, 1511\u20131525 (2008).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"Suppl. 2","key":"BFnrneph201058_CR54","first-page":"B53","volume":"22","author":"M Marre","year":"1999","unstructured":"Marre, M. Genetics and the prediction of complications in type 1 diabetes. Diabetes Care 22 (Suppl. 2), B53\u2013B58 (1999).","journal-title":"Diabetes Care"},{"key":"BFnrneph201058_CR55","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2337\/diabetes.46.1.19","volume":"46","author":"TJ Allen","year":"1997","unstructured":"Allen, T. J., Waldron, M. J., Casley, D., Jerums, G. & Cooper, M. E. Salt restriction reduces hyperfiltration, renal enlargement, and albuminuria in experimental diabetes. Diabetes 46, 19\u201324 (1997).","journal-title":"Diabetes"},{"key":"BFnrneph201058_CR56","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1161\/01.HYP.17.4.497","volume":"17","author":"B Fabris","year":"1991","unstructured":"Fabris, B., Jackson, B. & Johnston, C. I. Salt blocks the renal benefits of ramipril in diabetic hypertensive rats. Hypertension 17, 497\u2013503 (1991).","journal-title":"Hypertension"},{"key":"BFnrneph201058_CR57","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1681\/ASN.2007060693","volume":"19","author":"L Vogt","year":"2008","unstructured":"Vogt, L., Waanders, F., Boomsma, F., de Zeeuw, D. & Navis, G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J. Am. Soc. Nephrol. 19, 999\u20131007 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201058_CR58","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.2337\/dc08-2297","volume":"32","author":"EI Ekinci","year":"2009","unstructured":"Ekinci, E. I. et al. Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake. Diabetes Care 32, 1398\u20131403 (2009).","journal-title":"Diabetes Care"},{"key":"BFnrneph201058_CR59","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1159\/000057385","volume":"24","author":"B Cianciaruso","year":"1998","unstructured":"Cianciaruso, B. et al. Salt intake and renal outcome in patients with progressive renal disease. Miner. Electrolyte Metab. 24, 296\u2013301 (1998).","journal-title":"Miner. Electrolyte Metab."},{"key":"BFnrneph201058_CR60","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/BF02937197","volume":"154","author":"JA O'Hare","year":"1985","unstructured":"O'Hare, J. A. et al. Blood pressure may be sodium-dependent in diabetic patients without overt nephropathy. Ir. J. Med. Sci. 154, 455\u2013460 (1985).","journal-title":"Ir. J. Med. Sci."},{"key":"BFnrneph201058_CR61","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1159\/000057405","volume":"24","author":"MR Weir","year":"1998","unstructured":"Weir, M. R. Impact of salt intake on blood pressure and proteinuria in diabetes: importance of the renin-angiotensin system. Miner. Electrolyte Metab. 24, 438\u2013445 (1998).","journal-title":"Miner. Electrolyte Metab."},{"key":"BFnrneph201058_CR62","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/ki.1997.394","volume":"52","author":"JM De'Oliveira","year":"1997","unstructured":"De'Oliveira, J. M. et al. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney Int. 52, 771\u2013777 (1997).","journal-title":"Kidney Int."},{"key":"BFnrneph201058_CR63","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/ki.1992.138","volume":"41","author":"G Jerums","year":"1992","unstructured":"Jerums, G., Allen, T. J., Tsalamandris, C. & Cooper, M. E. Angiotensin converting enzyme inhibition and calcium channel blockade in incipient diabetic nephropathy. The Melbourne Diabetic Nephropathy Study Group. Kidney Int. 41, 904\u2013911 (1992).","journal-title":"Kidney Int."},{"key":"BFnrneph201058_CR64","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.numecd.2006.07.005","volume":"17","author":"SA Ritchie","year":"2007","unstructured":"Ritchie, S. A. & Connell, J. M. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr. Metab. Cardiovasc. Dis. 17, 319\u2013326 (2007).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"BFnrneph201058_CR65","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.mcna.2009.02.010","volume":"93","author":"E Reisin","year":"2009","unstructured":"Reisin, E. & Jack, A. V. Obesity and hypertension: mechanisms, cardio-renal consequences, and therapeutic approaches. Med. Clin. North Am. 93, 733\u2013751 (2009).","journal-title":"Med. Clin. North Am."},{"key":"BFnrneph201058_CR66","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1161\/01.HYP.0000132568.71409.a2","volume":"44","author":"AM Sharma","year":"2004","unstructured":"Sharma, A. M. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 44, 12\u201319 (2004).","journal-title":"Hypertension"},{"key":"BFnrneph201058_CR67","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1681\/ASN.2008040416","volume":"20","author":"E Burgess","year":"2009","unstructured":"Burgess, E. et al. Supramaximal dose of candesartan in proteinuric renal disease. J. Am. Soc. Nephrol. 20, 893\u2013900 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201058_CR68","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1097\/HJH.0b013e328277596e","volume":"25","author":"NK Hollenberg","year":"2007","unstructured":"Hollenberg, N. K. et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J. Hypertens. 25, 1921\u20131926 (2007).","journal-title":"J. Hypertens."},{"key":"BFnrneph201058_CR69","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/HJH.0b013e328332bd61","volume":"28","author":"MR Weir","year":"2010","unstructured":"Weir, M. R. et al. Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria. J. Hypertens. 28, 186\u2013193 (2010).","journal-title":"J. Hypertens."},{"key":"BFnrneph201058_CR70","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1681\/ASN.2006121372","volume":"18","author":"FF Hou","year":"2007","unstructured":"Hou, F. F. et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J. Am. Soc. Nephrol. 18, 1889\u20131898 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201058_CR71","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrneph.2009.77","volume":"5","author":"P Ruggenenti","year":"2009","unstructured":"Ruggenenti, P., Cravedi, P. & Remuzzi, G. Proteinuria: increased angiotensin-receptor blocking is not the first option. Nat. Rev. Nephrol. 5, 367\u2013368 (2009).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph201058_CR72","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1046\/j.1523-1755.2003.00940.x","volume":"63","author":"P Jacobsen","year":"2003","unstructured":"Jacobsen, P., Andersen, S., Rossing, K., Jensen, B. R. & Parving, H. H. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int. 63, 1874\u20131880 (2003).","journal-title":"Kidney Int."},{"key":"BFnrneph201058_CR73","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/ndt\/17.6.1019","volume":"17","author":"P Jacobsen","year":"2002","unstructured":"Jacobsen, P., Andersen, S., Rossing, K., Hansen, B. V. & Parving, H. H. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol. Dial. Transplant. 17, 1019\u20131024 (2002).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201058_CR74","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1097\/01.ASN.0000054495.96193.BF","volume":"14","author":"P Jacobsen","year":"2003","unstructured":"Jacobsen, P., Andersen, S., Jensen, B. R. & Parving, H. H. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J. Am. Soc. Nephrol. 14, 992\u2013999 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201058_CR75","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","volume":"321","author":"CE Mogensen","year":"2000","unstructured":"Mogensen, C. E. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321, 1440\u20131444 (2000).","journal-title":"BMJ"},{"key":"BFnrneph201058_CR76","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1046\/j.1523-1755.2003.00832.x","volume":"63","author":"R Campbell","year":"2003","unstructured":"Campbell, R. et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int. 63, 1094\u20131103 (2003).","journal-title":"Kidney Int."},{"key":"BFnrneph201058_CR77","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nrneph.2009.109","volume":"5","author":"P Ruggenenti","year":"2009","unstructured":"Ruggenenti, P. & Remuzzi, G. Proteinuria: is the ONTARGET renal substudy actually off target? Nat. Rev. Nephrol. 5, 436\u2013437 (2009).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph201058_CR78","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1056\/NEJM199604113341502","volume":"334","author":"G Maschio","year":"1996","unstructured":"Maschio, G. et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 334, 939\u2013945 (1996).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201058_CR79","first-page":"S63","volume":"63","author":"F Locatelli","year":"1997","unstructured":"Locatelli, F. et al. Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney Int. Suppl. 63, S63\u2013S66 (1997).","journal-title":"Kidney Int. Suppl."},{"key":"BFnrneph201058_CR80","doi-asserted-by":"publisher","first-page":"823","DOI":"10.2169\/internalmedicine.46.6415","volume":"46","author":"K Takaichi","year":"2007","unstructured":"Takaichi, K., Takemoto, F., Ubara, Y. & Mori, Y. Analysis of factors causing hyperkalemia. Intern. Med. 46, 823\u2013829 (2007).","journal-title":"Intern. Med."},{"key":"BFnrneph201058_CR81","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","volume":"372","author":"JF Mann","year":"2008","unstructured":"Mann, J. F. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372, 547\u2013553 (2008).","journal-title":"Lancet"},{"key":"BFnrneph201058_CR82","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/ncpneph0980","volume":"5","author":"M Epstein","year":"2009","unstructured":"Epstein, M. Re-examining RAS-blocking treatment regimens for abrogating progression of chronic kidney disease. Nat. Clin. Pract. Nephrol. 5, 12\u201313 (2009).","journal-title":"Nat. Clin. Pract. Nephrol."},{"key":"BFnrneph201058_CR83","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1532-5415.1985.tb07117.x","volume":"33","author":"RD Lindeman","year":"1985","unstructured":"Lindeman, R. D., Tobin, J. & Shock, N. W. Longitudinal studies on the rate of decline in renal function with age. J. Am. Geriatr. Soc. 33, 278\u2013285 (1985).","journal-title":"J. Am. Geriatr. Soc."},{"key":"BFnrneph201058_CR84","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1681\/ASN.2007090970","volume":"19","author":"P Ruggenenti","year":"2008","unstructured":"Ruggenenti, P. et al. Role of remission clinics in the longitudinal treatment of CKD. J. Am. Soc. Nephrol. 19, 1213\u20131224 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201058_CR85","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1463-1326.2005.00523.x","volume":"8","author":"I Os","year":"2006","unstructured":"Os, I., Gudmundsdottir, H., Kjeldsen, S. E. & Oparil, S. Treatment of isolated systolic hypertension in diabetes mellitus type 2. Diabetes Obes. Metab. 8, 381\u2013387 (2006).","journal-title":"Diabetes Obes. Metab."},{"key":"BFnrneph201058_CR86","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1046\/j.1523-1755.1999.055003984.x","volume":"55","author":"P Ruggenenti","year":"1999","unstructured":"Ruggenenti, P. et al. Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade. Kidney Int. 55, 984\u2013994 (1999).","journal-title":"Kidney Int."},{"key":"BFnrneph201058_CR87","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1172\/JCI27699","volume":"116","author":"G Remuzzi","year":"2006","unstructured":"Remuzzi, G., Benigni, A. & Remuzzi, A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J. Clin. Invest. 116, 288\u2013296 (2006).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph201058_CR88","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1681\/ASN.2004080632","volume":"16","author":"Z Zhang","year":"2005","unstructured":"Zhang, Z. et al. Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. J. Am. Soc. Nephrol. 16, 1775\u20131780 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201058_CR89","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/ncpneph0575","volume":"3","author":"AS Bomback","year":"2007","unstructured":"Bomback, A. S. & Klemmer, P. J. The incidence and implications of aldosterone breakthrough. Nat. Clin. Pract. Nephrol. 3, 486\u2013492 (2007).","journal-title":"Nat. Clin. Pract. Nephrol."},{"key":"BFnrneph201058_CR90","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s11906-006-0060-5","volume":"8","author":"GP Rossi","year":"2006","unstructured":"Rossi, G. P. Aldosterone breakthrough during RAS blockade: a role for endothelins and their antagonists? Curr. Hypertens. Rep. 8, 262\u2013268 (2006).","journal-title":"Curr. Hypertens. Rep."},{"key":"BFnrneph201058_CR91","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1093\/ndt\/gfp256","volume":"24","author":"GJ Becker","year":"2009","unstructured":"Becker, G. J., Hewitson, T. D. & Chrysostomou, A. Aldosterone in clinical nephrology\u2014old hormone, new questions. Nephrol. Dial. Transplant. 24, 2316\u20132321 (2009).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201058_CR92","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/clc.20324","volume":"31","author":"A Struthers","year":"2008","unstructured":"Struthers, A., Krum, H. & Williams, G. H. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin. Cardiol. 31, 153\u2013158 (2008).","journal-title":"Clin. Cardiol."},{"key":"BFnrneph201058_CR93","doi-asserted-by":"publisher","first-page":"F802","DOI":"10.1152\/ajprenal.00197.2009","volume":"297","author":"J Du","year":"2009","unstructured":"Du, J. et al. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats. Am. J. Physiol. Renal Physiol. 297, F802\u2013F808 (2009).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph201058_CR94","doi-asserted-by":"publisher","first-page":"F137","DOI":"10.1152\/ajprenal.00065.2008","volume":"295","author":"G Piecha","year":"2008","unstructured":"Piecha, G. et al. Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination. Am. J. Physiol. Renal Physiol. 295, F137\u2013F144 (2008).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph201058_CR95","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJM200109203451215","volume":"345","author":"A Chrysostomou","year":"2001","unstructured":"Chrysostomou, A. & Becker, G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N. Engl. J. Med. 345, 925\u2013926 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201058_CR96","doi-asserted-by":"publisher","first-page":"542","DOI":"10.2215\/CJN.04750908","volume":"4","author":"SD Navaneethan","year":"2009","unstructured":"Navaneethan, S. D., Nigwekar, S. U., Sehgal, A. R. & Strippoli, G. F. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol. 4, 542\u2013551 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201058_CR97","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1681\/ASN.2009070737","volume":"20","author":"UF Mehdi","year":"2009","unstructured":"Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L. & Toto, R. D. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 20, 2641\u20132650 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201058_CR98","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","volume":"70","author":"S Bianchi","year":"2006","unstructured":"Bianchi, S., Bigazzi, R. & Campese, V. M. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 70, 2116\u20132123 (2006).","journal-title":"Kidney Int."},{"key":"BFnrneph201058_CR99","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","volume":"24","author":"AH van den Meiracker","year":"2006","unstructured":"van den Meiracker, A. H. et al. Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J. Hypertens. 24, 2285\u20132292 (2006).","journal-title":"J. Hypertens."},{"key":"BFnrneph201058_CR100","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2215\/CJN.00240106","volume":"1","author":"M Epstein","year":"2006","unstructured":"Epstein, M. et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin. J. Am. Soc. Nephrol. 1, 940\u2013951 (2006).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201058_CR101","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1159\/000237742","volume":"30","author":"N Khosla","year":"2009","unstructured":"Khosla, N., Kalaitzidis, R. & Bakris, G. L. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am. J. Nephrol. 30, 418\u2013424 (2009).","journal-title":"Am. J. Nephrol."},{"key":"BFnrneph201058_CR102","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3810\/pgm.2009.05.2000","volume":"121","author":"RO Estacio","year":"2009","unstructured":"Estacio, R. O. Renin\u2013angiotensin\u2013aldosterone system blockade in diabetes: role of direct renin inhibitors. Postgrad. Med. 121, 33\u201344 (2009).","journal-title":"Postgrad. Med."},{"key":"BFnrneph201058_CR103","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1172\/JCI0214276","volume":"109","author":"G Nguyen","year":"2002","unstructured":"Nguyen, G. et al. Pivotal role of the renin\/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 109, 1417\u20131427 (2002).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph201058_CR104","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1113\/expphysiol.2007.040030","volume":"93","author":"G Nguyen","year":"2008","unstructured":"Nguyen, G. & Danser, A. H. Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents. Exp. Physiol. 93, 557\u2013563 (2008).","journal-title":"Exp. Physiol."},{"key":"BFnrneph201058_CR105","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1172\/JCI21398","volume":"114","author":"A Ichihara","year":"2004","unstructured":"Ichihara, A. et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the \u201chandle\u201d region for nonproteolytic activation of prorenin. J. Clin. Invest. 114, 1128\u20131135 (2004).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph201058_CR106","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2174\/138161207779313560","volume":"13","author":"J Eder","year":"2007","unstructured":"Eder, J., Hommel, U., Cumin, F., Martoglio, B. & Gerhartz, B. Aspartic proteases in drug discovery. Curr. Pharm. Des. 13, 271\u2013285 (2007).","journal-title":"Curr. Pharm. Des."},{"key":"BFnrneph201058_CR107","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dc09-0168","volume":"32","author":"F Persson","year":"2009","unstructured":"Persson, F. et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 32, 1873\u20131879 (2009).","journal-title":"Diabetes Care"},{"key":"BFnrneph201058_CR108","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","volume":"358","author":"HH Parving","year":"2008","unstructured":"Parving, H. H., Persson, F., Lewis, J. B., Lewis, E. J. & Hollenberg, N. K. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433\u20132446 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201058_CR109","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.1365-2125.2004.02197.x","volume":"58","author":"S Garattini","year":"2004","unstructured":"Garattini, S. & Bertele, V. Risk:benefit assessment of old medicines. Br. J. Clin. Pharmacol. 58, 581\u2013586 (2004).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BFnrneph201058_CR110","doi-asserted-by":"publisher","first-page":"11","DOI":"10.7326\/0003-4819-151-1-200907070-00120","volume":"151","author":"R Bilous","year":"2009","unstructured":"Bilous, R. et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann. Intern. Med. 151, 11\u201320 (2009).","journal-title":"Ann. Intern. Med."},{"key":"BFnrneph201058_CR111","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2337\/diacare.28.2.273","volume":"28","author":"NH Andersen","year":"2005","unstructured":"Andersen, N. H. et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care 28, 273\u2013277 (2005).","journal-title":"Diabetes Care"},{"key":"BFnrneph201058_CR112","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2337\/diacare.25.1.95","volume":"25","author":"K Rossing","year":"2002","unstructured":"Rossing, K., Christensen, P. K., Jensen, B. R. & Parving, H. H. Dual blockade of the renin\u2013angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 25, 95\u2013100 (2002).","journal-title":"Diabetes Care"},{"key":"BFnrneph201058_CR113","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.2337\/diacare.26.8.2268","volume":"26","author":"K Rossing","year":"2003","unstructured":"Rossing, K., Jacobsen, P., Pietraszek, L. & Parving, H. H. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 26, 2268\u20132274 (2003).","journal-title":"Diabetes Care"},{"key":"BFnrneph201058_CR114","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s592-001-8073-2","volume":"38","author":"NB Tutuncu","year":"2001","unstructured":"Tutuncu, N. B., Gurlek, A. & Gedik, O. Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. Acta Diabetol. 38, 157\u2013161 (2001).","journal-title":"Acta Diabetol."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2010.58.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2010.58","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2010.58.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:34:27Z","timestamp":1684470867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2010.58"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,4]]},"references-count":114,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["BFnrneph201058"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2010.58","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,4]]}}}